New England Biolabs (NEB®) today announces the release of the NEBNext Flu A Integrated Indexing Primer Module (NEB #E3436), ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Novartis phase III trial for next-generation malaria treatment KLU156 meets primary endpoint, with potential to combat antimalarial resistance: Basel Friday, November 14, 2025, 09 ...
In this Q&A, Pratt discusses a recent study comparing multiplex droplet digital PCR (ddPCR) with traditional quantitative PCR (qPCR), highlighting key methodological differences, assay validation ...
Novartis (NVS) stock is in focus as the company announces a late-stage trial win for its new malaria drug GanLum developed ...
A new malaria drug, Ganaplacide/Lumefantrine, shows over 97% cure rates in trials. This treatment is effective even where ...
Despite strong evidence for metronidazole, amoebiasis persists as a global burden, highlighting gaps in diagnostics and ...
The review also calls for embedding diagnostics within the One Health framework, which integrates human, animal, and ...
Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Swiss pharma giant Novartis has announced positive results from KALUMA, a Phase III study for new malaria treatment KLU156 (ganaplacide/lumefantrine, or GanLum).
Health authorities urge clinicians to check vaccination status and watch for chronic or worsening wounds, especially in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback